Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2007 December;73(12) > Minerva Anestesiologica 2007 December;73(12):647-50

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEW ARTICLES   Freefree

Minerva Anestesiologica 2007 December;73(12):647-50

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

My brother has severe sepsis - Should he receive Xigris®?

Suter P. M.

University of Geneva, Switzerland


PDF


Six years ago, a publication in a quite well known scientific medical journal brought hope and a good dose of optimism to sepsis therapy and the critical care community. For the first time, a careful randomized controlled trial in patients with severe sepsis or septic shock seemed to show a clearly beneficial effect of a new drug, i.e. of activated recombinant human protein C. This new treatment possibility was welcomed as an important breakthrough and a hope for a better management of a deadly disease. However, further evaluation of the results of the trial and new investigations did not confirm entirely the initial optimism. As a consequence, the adequate indications for this expensive drug remain controversial.

top of page